Equities analysts expect that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will announce earnings of ($0.17) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.12). Conatus Pharmaceuticals reported earnings per share of ($0.35) in the same quarter last year, which indicates a positive year-over-year growth rate of 51.4%. The business is scheduled to announce its next earnings report on Wednesday, March 21st.

Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.08). The company had revenue of $9.57 million for the quarter, compared to analysts’ expectations of $16.06 million. Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 83.02%. During the same quarter in the prior year, the business posted ($0.31) earnings per share.

CNAT has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Stifel Nicolaus restated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Seaport Global Securities restated a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $16.00.

Several large investors have recently modified their holdings of CNAT. Voya Investment Management LLC acquired a new stake in shares of Conatus Pharmaceuticals in the second quarter worth approximately $101,000. Wells Fargo & Company MN boosted its stake in shares of Conatus Pharmaceuticals by 3,098.0% in the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 18,588 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Conatus Pharmaceuticals in the second quarter worth approximately $109,000. FNY Partners Fund LP boosted its stake in shares of Conatus Pharmaceuticals by 98.0% in the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 9,800 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Conatus Pharmaceuticals in the second quarter worth approximately $115,000. 34.06% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/21/analysts-anticipate-conatus-pharmaceuticals-inc-cnat-to-announce-0-17-eps.html.

Shares of Conatus Pharmaceuticals (CNAT) traded down $0.14 during mid-day trading on Friday, reaching $4.08. The company had a trading volume of 175,200 shares, compared to its average volume of 619,267. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.69 and a quick ratio of 2.69. Conatus Pharmaceuticals has a 52 week low of $1.73 and a 52 week high of $9.40.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.